Nothing Special   »   [go: up one dir, main page]

EA201691599A1 - COMBINATION OF TAURINE AND RACEMETIONINE FOR THE TREATMENT OF LIVER DISEASES - Google Patents

COMBINATION OF TAURINE AND RACEMETIONINE FOR THE TREATMENT OF LIVER DISEASES

Info

Publication number
EA201691599A1
EA201691599A1 EA201691599A EA201691599A EA201691599A1 EA 201691599 A1 EA201691599 A1 EA 201691599A1 EA 201691599 A EA201691599 A EA 201691599A EA 201691599 A EA201691599 A EA 201691599A EA 201691599 A1 EA201691599 A1 EA 201691599A1
Authority
EA
Eurasian Patent Office
Prior art keywords
taurine
formulation
amount
composition
racemetionine
Prior art date
Application number
EA201691599A
Other languages
Russian (ru)
Inventor
Камлеш Раджникант Зота
Санджай Агравал
Кетан Чхандулал Зота
Манукант Чхандулал Зота
Химаншу Муктилал Зота
Original Assignee
Зота Хэлс Кэа Лтд.
Камлеш Раджникант Зота
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зота Хэлс Кэа Лтд., Камлеш Раджникант Зота filed Critical Зота Хэлс Кэа Лтд.
Publication of EA201691599A1 publication Critical patent/EA201691599A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В настоящем изобретении описывается синергидная пероральная композиция, содержащая таурин и рацеметионин, где количество таурина берется в диапазоне от 250 до 500 мг, а количество рацеметионина берется в диапазоне от 100 до 200 мг по весу композиции, при этом активный вес дает в результате терапевтически, синергидно эффективную пероральную композицию с целью получения вместе с другими фармацевтическими наполнителями безопасной и эффективной лекарственной формы. Указанная композиция предусматривает различные профили высвобождения лекарственного средства, такие как состав длительного или контролируемого или замедленного действия, доступные в виде состава для перорального применения (капсула, таблетка, гранулы и сироп) и незамедлительную активность в отношении нарушений функции печени, активные антиоксидантные свойства, обусловленные синергидно эффективным количеством таурина и рацеметионина в составе, при этом вышеуказанное эффективное количество для получения состава берется вместе с подходящими наполнителями, добавками и разделительными средствами.The present invention describes a synergistic oral composition comprising taurine and racemetionin, where the amount of taurine is taken in the range from 250 to 500 mg, and the amount of racemetionin is taken in the range from 100 to 200 mg by weight of the composition, while the active weight results in a therapeutically, synergistic an effective oral composition in order to obtain, together with other pharmaceutical excipients, a safe and effective dosage form. This composition provides various drug release profiles, such as a long-term or controlled or slow-acting formulation, available as an oral formulation (capsule, tablet, granules, and syrup) and immediate activity on liver dysfunction, active antioxidant properties due to synergism an effective amount of taurine and racemetionine in the formulation, with the aforementioned effective amount for preparing the formulation being taken along with walking, fillers, additives and the separating means.

EA201691599A 2014-05-19 2014-08-01 COMBINATION OF TAURINE AND RACEMETIONINE FOR THE TREATMENT OF LIVER DISEASES EA201691599A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1668MU2014 2014-05-19
PCT/IN2014/000510 WO2015177805A1 (en) 2014-05-19 2014-08-01 Combination of taurine and racemethionine for treatment of liver diseases

Publications (1)

Publication Number Publication Date
EA201691599A1 true EA201691599A1 (en) 2016-11-30

Family

ID=51903973

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691599A EA201691599A1 (en) 2014-05-19 2014-08-01 COMBINATION OF TAURINE AND RACEMETIONINE FOR THE TREATMENT OF LIVER DISEASES

Country Status (3)

Country Link
AP (1) AP2016009662A0 (en)
EA (1) EA201691599A1 (en)
WO (1) WO2015177805A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817695A (en) 1997-12-24 1998-10-06 Pellico; Michael A. Nutritional product with high fat, low carbohydrate and amino acid imbalance
US20070185194A1 (en) * 2003-07-01 2007-08-09 Kamal Mehta Stable oral compositions of azithromycin monohydrate
KR100549697B1 (en) 2004-12-10 2006-02-07 김세규 Amino acid supplement food
WO2011045810A1 (en) * 2009-08-13 2011-04-21 Zota Health Care Limited Pharmaceutical compositions containing taurine and race-methionine for the treatment of alcoholism
WO2013124860A1 (en) * 2012-02-23 2013-08-29 Zota Health Care Ltd Potent revital formulation

Also Published As

Publication number Publication date
AP2016009662A0 (en) 2016-12-31
WO2015177805A1 (en) 2015-11-26

Similar Documents

Publication Publication Date Title
EA201892395A1 (en) DRUG COMPOSITIONS OF LSD1 INHIBITOR
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
EA201691454A1 (en) COMPOSITIONS OF PRIDOPIDININE MODIFIED SHIPPING
CR20180253A (en) THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HUMAN UNMUNODEFICIENCY VIRUS
EA202090573A1 (en) COMPOSITIONS OF NIRAPARIBA
EA201992116A1 (en) PHARMACEUTICAL COMPOSITIONS OF FLOROGLUCINOL AND TRIMETHYLFLOROGLUCINOL
CO2016003340A2 (en) Pharmaceutical formulations, processes for preparation and methods of use
MX2019012522A (en) Therapeutic compounds and methods.
MX2017013636A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from different particles.
MX2017013099A (en) Methods for the treatment of inflammatory disorders.
MX2017005163A (en) Onapristone extended-release compositions and methods.
MX2016010892A (en) Agent for improving or preventing progression of chronic kidney disease.
EA201892837A1 (en) PHYSIOLOGICALLY BALANCED COMPOUNDS FOR INJECTIONS, INCLUDING PHOSNET SUPPORTANT
MX2017013633A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from particles.
MX2018006631A (en) Compound for use in the prevention and treatment of neurodegenerative diseases.
EA201792170A1 (en) INDOLA DERIVATIVES
EA201691599A1 (en) COMBINATION OF TAURINE AND RACEMETIONINE FOR THE TREATMENT OF LIVER DISEASES
PH12020500120A1 (en) Pharmaceutical compositions
PH12016502540A1 (en) Pharmaceutical dosage forms
MD3439637T2 (en) Process for mesalazine solid formulations
EA201790089A1 (en) PHARMACEUTICAL MEANS FOR THE TREATMENT OF THE HEAD OF VARIOUS ETIOLOGY
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically
EA201992754A1 (en) PHARMACEUTICAL COMPOSITIONS
EA201592261A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING AGOMELATIN IN THE FORM OF HOMELATIN CRYSTALS WITH ORGANIC ACID